<abstract xmlns="http://www.w3.org/1999/xhtml">

<p>This article is aimed to provide an overview of psoriasis clinical aspects, available treatment options for moderate-to-severe psoriasis in Baltics and summarises recommendations of authors for use of different biologicals in psoriasis patients under a limited reimbursement environment.</p>
</abstract>

This article is aimed to provide an overview of psoriasis clinical aspects, available treatment options for moderate-to-severe psoriasis in Baltics and summarises recommendations of authors for use of different biologicals in psoriasis patients under a limited reimbursement environment.

Immunopathogenic Treatment Options for Psoriasis Patients Under a Restrictive Reimbursement Environment

Proceedings of the Latvian Academy of Sciences. Section B. Natural, Exact, and Applied Sciences.

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

This article is aimed to provide an overview of psoriasis clinical aspects, available treatment options for moderate-to-severe psoriasis in Baltics and...

Immunopathogenic Treatment Options for Psoriasis Patients Under a Restrictive Reimbursement Environment

Publié en ligne: 22 juil. 2021

Pages: 158 - 166

Reçu: 11 juin 2020

Accepté: 01 mars 2021

DOI: https://doi.org/10.2478/prolas-2021-0025

Mots clés
autoimmune skin disorder, biological therapy, state compensation, Baltic

© 2020 Ilona Hartmane et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Immunopathogenic Treatment Options for Psoriasis Patients Under a Restrictive Reimbursement Environment

Publié en ligne: 22 juil. 2021

Pages: 158 - 166

Reçu: 11 juin 2020

Accepté: 01 mars 2021

DOI: https://doi.org/10.2478/prolas-2021-0025

Mots clésautoimmune skin disorder, biological therapy, state compensation, Baltic

© 2020 Ilona Hartmane et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Mots clés
autoimmune skin disorder, biological therapy, state compensation, Baltic